Orphan Designations Block 340B Discounts on Multi-Use Drugs at Critical Access Hospitals

{"The 2010 Affordable Care Act expanded 340B eligibility to critical access hospitals but allowed manufacturers to exclude orphan-designated drugs at their discretion. Court rulings in 2014 and 2015 struck down HRSA attempts to tie exclusions to actual use, ruling that only Congress could shift the statute from designation-based to indication-based criteria. This left small rural pharmacies absorbing full wholesale costs on multi-indication agents.","Rinvoq carries an orphan designation for juvenile idiopathic arthritis yet is commonly prescribed for Crohn’s disease. The Nebraska pharmacist reports selling at a loss because the designation travels with the molecule. HRSA’s August 2026 rebate pilot, effective January 2027, requires full-price purchase followed by claims-based rebates, with manufacturers choosing participation while covered entities cannot opt out.","Electronic claims data now make indication tracking feasible, removing the 2013 practicality barrier cited by courts. Persistent designation-based exclusions concentrate financial pressure on rural facilities already serving dispersed populations, potentially reducing local specialty-pharmacy access and increasing reliance on distant mail-order channels.","If manufacturers limit pilot participation, losses will persist; broader uptake could restore margins but requires verified indication data and timely rebates. Congress has not amended the statute, leaving the gap intact unless new legislation redefines the exclusion around clinical use."}